Semaglutide side effects, safety profile, and management strategies.
What the clinical data shows about semaglutide side effects — incidence rates from the STEP trials, GI management strategies, the hair loss question, cancer boxed warning context, long-term safety data, and when to contact your prescribing provider.
Common side effects of semaglutide
The most frequently reported side effects are gastrointestinal — a direct consequence of GLP-1 receptor activation slowing gastric emptying and altering gut motility. These effects are most common during dose escalation and typically diminish at maintenance dose.
| Side effect | Semaglutide | Placebo | Typically resolves |
|---|---|---|---|
| Nausea | 44% | 18% | 2–4 weeks after dose stabilization |
| Diarrhea | 30% | 16% | 1–3 weeks |
| Vomiting | 24% | 6% | 1–2 weeks |
| Constipation | 24% | 10% | Ongoing for some |
| Abdominal pain | 20% | 11% | 1–3 weeks |
| Headache | 14% | 13% | First week |
| Fatigue | 11% | 5% | 2–4 weeks |
Semaglutide nausea: management
Nausea is the most reported side effect and the primary reason patients consider stopping. It is usually transient and manageable:
- Eat smaller, more frequent meals — large meals sit in the stomach longer
- Avoid high-fat and fried foods — fat compounds the delayed gastric emptying
- Stay hydrated — dehydration worsens nausea
- Inject before bedtime — sleep through peak GI effects (6–12 hours post-injection)
- Slow your titration — compounded semaglutide allows intermediate doses for more gradual escalation
If nausea persists beyond 3–4 weeks at a given dose, contact your provider. Dose reduction or slower titration are standard approaches.
Semaglutide and hair loss
Hair loss was reported in approximately 3% of semaglutide patients vs 1% on placebo. The most likely explanation is telogen effluvium — temporary diffuse shedding triggered by rapid weight loss and caloric deficit, not a direct pharmacological effect. It typically occurs 2–4 months after significant caloric reduction and is self-limiting.
To minimize: maintain adequate protein intake (0.8–1.0 g per pound of lean mass), supplement biotin/iron/zinc/vitamin D if low, and avoid extreme caloric restriction.
Semaglutide side effects and cancer
Semaglutide carries a boxed warning regarding thyroid C-cell tumors. In rodent studies, GLP-1 agonists caused dose-dependent medullary thyroid carcinoma (MTC). However, rodents have significantly higher GLP-1 receptor density on thyroid C-cells than humans, and no causal link has been established in humans across multiple large-scale trials.
Semaglutide is contraindicated in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Semaglutide long-term side effects
The SELECT cardiovascular outcomes trial (median follow-up 39.8 months) showed semaglutide reduced major adverse cardiovascular events by 20% — indicating cardiovascular benefit with extended use. Ongoing considerations:
- Gallbladder disease — increased gallstone rates during rapid weight loss
- Pancreatitis — rare but reported; discontinue if suspected
- Muscle loss — ~40% of weight lost is lean mass; resistance training recommended
- Weight regain after stopping — STEP 4 showed ~two-thirds of weight regained within one year of discontinuation
When to contact your prescriber
- Severe abdominal pain that does not resolve (possible pancreatitis)
- Vision changes (diabetic retinopathy in diabetic patients)
- Signs of allergic reaction — facial swelling, difficulty breathing, severe rash
- Persistent vomiting or inability to keep fluids down for 24+ hours
- A lump or swelling in your neck, hoarseness, or difficulty swallowing